BioNTech Entered into a Multi-Target Research Collaboration with Ryvu Therapeutics to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates
Shots:
- Ryvu will receive $20.89M up front in exchange for rights to Ryvu’s STING agonist portfolio, $20.89M in equity investment & is also eligible to receive R&D and commercial milestones along with royalties. BioNTech obtains an option to license rights globally to develop & commercialize the programs at the development stage
- BioNTech also gets an exclusive license globally for Ryvu’s STING agonist portfolio as standalone small molecules & will fund all discovery, research & development activities, incl. Ryvu’s discovery & research activities
- The companies jointly responsible for drug discovery & research projects to develop multiple small molecule programs at exclusive targets with initial focuses on immune modulation in oncology
Ref: Globenewswire | Image: BioNTech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
